Navigation Links
Calvert Labs Announces the Hiring of Terry Ladd
Date:1/28/2009

Terry Ladd (MBA, MA) rejoins Calvert Labs as VP of Business Development

Olyphant, PA (PRWEB) January 28, 2009 -- Calvert Labs, a Calvert Holdings, Inc. company, announced today the hiring of Mr. Terry Ladd as Vice President of Business Development. Mr. Ladd had worked at Calvert Labs from 1994-2003 as Executive Director, Business Development and Marketing.

Mr. Ladd will be responsible for the sales and marketing of preclinical services in North America. With his many years of experience in the drug development/contract research organization field, he brings significant wisdom and experience to the table to help clients attain their goals in drug development in a timely and proper manner.

In addition to earning an MBA from McGill University and an MA from the University of Sherbrooke, Mr. Ladd's well-rounded background includes experience managing the sales, marketing, business development, finance, and administration functions for companies as varied as IMS Health, Guillevin International, Supertel Video Productions and General Electric.

Allan Reiss, President and COO of Calvert Holdings, Inc. remarked: "Although given opportunities to continue a successful career within larger pharma organizations, Mr. Ladd chose to return to a younger, innovative company that has a proven track record within the industry. We are honored that he has chosen to return." Mr. Ladd responded: "I am glad to be back with my former colleagues and look forward to the challenges and successes ahead."

About Calvert Labs:
Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades. As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology. Located in northeastern Pennsylvania and easily accessible by major airlines, Calvert Labs provides services to companies in the biotechnology, pharmaceutical, and chemical industrial sectors.

About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe. Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

###

Read the full story at http://www.prweb.com/releases/2009/01/prweb1918114.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Calvert Research and Auburn University Announce Joint Venture
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
3. Indevus Pharmaceuticals Announces Release of 2008 Annual Report
4. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
5. Cardium Announces Retirement of Director
6. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business Objectives
9. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
10. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
11. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Calvert Labs Announces the Hiring of Terry Ladd 
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):